Surapol Issaragrisil

Surapol Issaragrisil

Auto-generated profile, based on publicly available information

Surapol Issaragrisil

Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GSGiuseppe Saglio
Giuseppe Saglio
DKDong-Wook Kim
Dong-Wook Kim
SISurapol Issaragrisil
Surapol Issaragrisil
PCPhilipp Le Coutre
Philipp Le Coutre
GEGabriel Etienne
Gabriel Etienne
EIENESTnd Investigators
ENESTnd Investigators
Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (CML) in the chronic phase. In this phase 3, randomized, open-label, multicenter study, we assigned 846 patients with chronic-phase Philadelphia chromosome–positive CML in a 1:1:1 ratio to receive nilotinib (at a dose of either 300 mg or 400 mg twice daily) or imatinib (at a dose of 400 mg once daily). The primary end point was the rate of major molecular response at 12 months. At 12 months, the rates of major molecular response for nilotinib (44% for the 300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%) (P<0.001 for both comparisons). The rates of complete cytogenetic response by 12 months were significantly higher for nilotinib (80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%) (P<0.001 for both comparisons). Patients receiving either the 300-mg dose or the 400-mg dose of nilotinib twice daily had a significant improvement in the time to progression to the accelerated phase or blast crisis, as compared with those receiving imatinib (P=0.01 and P=0.004, respectively). No patient with progression to the accelerated phase or blast crisis had a major molecular response. Gastrointestinal and fluid-retention events were more frequent among patients receiving imatinib, whereas dermatologic events and headache were more frequent in those receiving nilotinib. Discontinuations due to aminotransferase and bilirubin elevations were low in all three study groups. Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome–positive CML. (ClinicalTrials.gov number, NCT00471497.)

1 January 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
PAPaweorn Angsutararux
Paweorn Angsutararux
SLSudjit Luanpitpong
Sudjit Luanpitpong
SISurapol Issaragrisil
Surapol Issaragrisil
Chemotherapy-induced cardiotoxicity is a serious complication that poses a serious threat to life and limits the clinical use of various chemotherapeutic agents, particularly the anthracyclines. Understanding molecular mechanisms of chemotherapy-induced cardiotoxicity is a key to effective preventive strategies and improved chemotherapy regimen. Although no reliable and effective preventive treatment has become available, numerous evidence demonstrates that chemotherapy-induced cardiotoxicity involves the generation of reactive oxygen species (ROS). This review provides an overview of the roles of oxidative stress in chemotherapy-induced cardiotoxicity using doxorubicin, which is one of the most effective chemotherapeutic agents against a wide range of cancers, as an example. Current understanding in the molecular mechanisms of ROS-mediated cardiotoxicity will be explored and discussed, with emphasis on cardiomyocyte apoptosis leading to cardiomyopathy. The review will conclude with perspectives on model development needed to facilitate further progress and understanding on chemotherapy-induced cardiotoxicity.

15 February 2006 in Blood
Verified
Journal Article
Open access
PDF file
SISurapol Issaragrisil
Surapol Issaragrisil
DKDavid W. Kaufman
David W. Kaufman
TATheresa Anderson
Theresa Anderson
KCKanchana Chansung
Kanchana Chansung
PLPaul E. Leaverton
Paul E. Leaverton
NYNeal S. Young
Neal S. Young
Aplastic anemia has been linked to environmental exposures, from chemicals and medical drugs to infectious agents. The disease occurs more frequently in Asia than in the West, with incidence rates 2- to 3-fold higher. We report updated results of an epidemiologic study conducted in Thailand from 1989 to 2002, in which 541 patients and 2261 controls were enrolled. Exposures were determined by in-person interview. We observed significantly elevated relative risk estimates for benzene (3.5) and other solvents (2.0) and for sulfonamides (5.6), thiazides (3.8), and mebendazole (3.0). Chloramphenicol use was infrequent, and no significant association was observed. Agricultural pesticides were implicated in Khonkaen (northeastern Thailand). There were significant associations with organophosphates (2.1), DDT (6.7), and carbamates (7.4). We found significant risks for farmers exposed to ducks and geese (3.7) and a borderline association with animal fertilizer (2.1). There was a significant association in Khonkaen with drinking other than bottled or distilled water (2.8). Nonmedical needle exposure was associated in Bangkok and Khonkaen combined (3.8). Most striking was the large etiologic fraction in a rural region accounted for by animal exposures and drinking of water from sources such as wells, rural taps, and rainwater, consistent with an infectious etiology for many cases of aplastic anemia in Thailand.

1 December 1996 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
DKDavid W. Kaufman
David W. Kaufman
JKJudith P. Kelly
Judith P. Kelly
JJJan M. Jurgelon
Jan M. Jurgelon
TATheresa Anderson
Theresa Anderson
SISurapol Issaragrisil
Surapol Issaragrisil
SSSamuel Shapiro
Samuel Shapiro

23 November 2012 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
SMS. Manochantr
S. Manochantr
YUY. U‐Pratya
Y. U‐Pratya
PKP. Kheolamai
P. Kheolamai
SRS. Rojphisan
S. Rojphisan
MCM. Chayosumrit
M. Chayosumrit
SIS. Issaragrisil
S. Issaragrisil

9 February 1995 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SISurapol Issaragrisil
Surapol Issaragrisil
SVSanan Visuthisakchai
Sanan Visuthisakchai
VSVinai Suvatte
Vinai Suvatte
VTVoravarn S. Tanphaichitr
Voravarn S. Tanphaichitr
DCDasnayanee Chandanayingyong
Dasnayanee Chandanayingyong
APAnong Piankijagum
Anong Piankijagum
Several different kinds of thalassemia and hemoglobinopathy are prevalent in Southeast Asia.1,2 The frequency of the α-thalassemias reaches 30 to 40 percent in northern Thailand, whereas the β-thalassemias occur at a frequency of 3 to 9 percent. Hemoglobin E, the hallmark hemoglobinopathy of Southeast Asia, occurs at a frequency of 50 to 60 percent at the junction of Thailand, Laos, and Cambodia. Mutation and gene interaction account for more than 60 different clinical syndromes. Of these, homozygous β-thalassemia and hemoglobin E –β-thalassemia disease are the most common and the most severe clinical syndromes compatible with live birth. Hemoglobin E–β-thalassemia disease is more frequent than homozygous β-thalassemia in Southeast Asia because of the much higher frequency of hemoglobin E.